NDAINJECTIONINJECTABLE
Approved
Dec 1944
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Aminohippurate sodium is a diagnostic agent administered via injection that has been used historically for renal function assessment and imaging. The drug works by being rapidly cleared by renal tubular secretion, making it useful for measuring effective renal plasma flow and kidney imaging studies. It is a legacy diagnostic radiopharmaceutical with limited current clinical applications.
LOE Approaching
As a legacy diagnostic agent nearing loss of exclusivity with minimal market penetration, this product supports a small specialized team rather than a growth-oriented commercial organization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on aminohippurate sodium offers limited career growth given its LOE-approaching status and minimal linked job openings. Roles are primarily focused on compliance, operational efficiency, and managed decline rather than innovation or market expansion.
Diagnostic Product ManagerMedical Science Liaison
Worked on AMINOHIPPURATE SODIUM at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.